实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (5): 475-477.doi: 10.3969/j.issn.1672-5069.2012.05.0040
吴文睿 综述, 刘超 审校
收稿日期:
2012-03-10
出版日期:
2012-10-10
发布日期:
2017-03-09
通讯作者:
刘超,E-mail:mdliuchao@hotmail.com
作者简介:
吴文睿 男,24岁,硕士研究生。主要从事肝癌起源的研究。
Received:
2012-03-10
Online:
2012-10-10
Published:
2017-03-09
摘要: 研究信号通路在肝脏中各自的调节机制及相互作用,深入探讨肝癌发生、发展的机制,可以为寻找新的治疗靶点提供理论依据。本文介绍了Wnt与Notch信号通路在肝脏功能发挥及其在肝癌发生发展中的作用。
吴文睿 综述, 刘超 审校. Wnt和Notch信号通路在肝癌发生发展中的作用研究进展[J]. 实用肝脏病杂志, 2012, 15(5): 475-477.
[1] Lee C H,Chang C J,Lin Y J,et al. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer,2009,100(11):1765-1770. [2] Zhou H,Wang H,Zhou D,et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer,2010,46(6):1056-1061. [3] Spee B,Carpino G,Schotanus B A,et al. Characterisation of the liver progenitor cell niche in liver diseases:potential involvement of Wnt and Notch signalling. Gut,2010,59(2):247-257. [4] Nelson W J,Nusse R. Convergence of Wnt,beta-catenin, and cadherin pathways. Science,2004,303(5663):1483-1487. [5] Clevers H. Wnt/beta-catenin signaling in development and disease. Cell,2006,127(3):469-480. [6] Cadigan K M,Liu Y I. Wnt signaling:complexity at the surface. J Cell Sci,2006,119(Pt 3):395-402. [7] Logan C Y,Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol,2004,20:781-810. [8] Lilien J,Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol,2005,17(5):459-465. [9] Cheng A S,Lau S S,Chen Y,et al. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Res,2011,71(11):4028-4039. [10] Wolfe A,Thomas A,Edwards G,et al. Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther,2011,338(1):12-21. [11] Wang X H,Meng X W,Sun X,et al. Wnt/beta-catenin signaling regulates MAPK and Akt1 expression and growth of hepatocellular carcinoma cells. Neoplasma,2011,58(3):239-244. [12] Jia Y,Yang Y,Liu S,et al. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics,2010,5(8):743-749. [13] Uematsu S,Higashi T,Nouso K,et al. Altered expression of vascular endothelial growth factor,fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol,2005,20(4):583-588. [14] Zhang X,Gaspard J P,Chung D C. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res,2001,61(16):6050-6054. [15] Gao C,Guo H,Downey L,et al. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis,2003,24(12):1871-1878. [16] Colnot S,Decaens T,Niwa-Kawakita M,et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A,2004,101(49):17216-17221. [17] Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev,2006,32(1):28-44. [18] Dempke W,Rie C,Grothey A,et al. Cyclooxygenase-2: a novel target for cancer chemotherapy?J Cancer Res Clin Oncol, 2001,127(7):411-417. [19] Sun M H,Han X C,Jia M K,et al. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol,2005,11(38):5931-5937. [20] Yuzugullu H,Benhaj K,Ozturk N,et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer,2009,8:90. [21] Toyama T,Lee H C,Koga H,et al. Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res,2010,8(2):254-265. [22] Fiuza U M,Arias A M. Cell and molecular biology of Notch. J Endocrinol,2007,194(3):459-474. [23] Mazieres J,He B,You L,et al. Wnt signaling in lung cancer. Cancer Lett,2005,222(1):1-10. [24] Logeat F,Bessia C,Brou C,et al. The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci USA,1998,95(14):8108-8112. [25] Nijjar S S,Crosby H A,Wallace L,et al. Notch receptor expression in adult human liver:a possible role in bile duct formation and hepatic neovascularization. Hepatology,2001,34(6):1184-1192. [26] Nam Y,Sliz P,Song L,et al. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell,2006,124(5):973-983. [27] Zhou S,Fujimuro M,Hsieh J J,et al. SKIP,a CBF1-associated protein,interacts with the ankyrin repeat domain of NotchIC To facilitate NotchIC function. Mol Cell Biol,2000,20(7):2400-2410. [28] Kovall R A. Structures of CSL,Notch and Mastermind proteins: piecing together an active transcription complex. Curr Opin Struct Biol,2007,17(1):117-127. [29] Martinez J C,Muller M M,Turley H,et al. Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4(DLL4)in normal and malignant human tissues. Histopathology,2009,54(5):598-606. [30] Radtke F,Raj K. The role of Notch in tumorigenesis:oncogene or tumour suppressor? Nat Rev Cancer,2003,3(10):756-767. [31] Qi R,An H,Yu Y,et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res,2003,63(23):8323-8329. [32] Croquelois A,Blindenbacher A,Terracciano L,et al. Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology,2005,41(3):487-496. [33] Ma S,Chan K W,Hu L,et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology,2007,132(7):2542-2556. [34] Giovannini C,Lacchini M,Gramantieri L,et al. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res,2006,26(3A):2123-2127. [35] Ishimura N,Bronk S F,Gores G J. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol,2004,287(1):G88-G95. [36] Ishii T,Yasuchika K,Suemori H,et al. Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma. Cancer Lett,2010,294(1):25-34. [37] Fukutomi T,Zhou Y,Kawai S,et al. Hepatitis C virus core protein stimulates hepatocyte growth:correlation with upregulation of wnt-1 expression. Hepatology,2005,41(5):1096-1105. [38] Lee T H,Tai D I,Cheng C J,et al. Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics. J Biomed Sci,2006,13(1):27-39. [39] DeMorrow S,Francis H,Gaudio E,et al. The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. Am J Physiol Gastrointest Liver Physiol,2008,295(6):G1150-G1158. [40] Wang M,Xue L,Cao Q,et al. Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma,2009,56(6):533-541. |
[1] | 曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899. |
[2] | 朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723. |
[3] | 王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727. |
[4] | 戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨* [J]. 实用肝脏病杂志, 2019, 22(4): 561-564. |
[5] | 杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580. |
[6] | 彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376. |
[7] | 乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424. |
[8] | 朱光曦(综述), 文良志, 陈东风(审校). 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456. |
[9] | 王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251. |
[10] | 幸奠奎,程婧. 18F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254. |
[11] | 王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 *[J]. 实用肝脏病杂志, 2019, 22(2): 260-263. |
[12] | 张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271. |
[13] | 王朝霞,关珂,付三仙,王慧杰. 肠内肠外联合营养支持治疗肝细胞癌患者围术期临床研究*[J]. 实用肝脏病杂志, 2019, 22(2): 272-275. |
[14] | 赵西太综述,聂青和审校. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨[J]. 实用肝脏病杂志, 2019, 22(2): 297-300. |
[15] | 范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||